Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

Kate Ellis '25 took time away from classes to prioritize the needs of a leukemia patient she had never met, making a ...

The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...

Revelation Biosciences (REVB) announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells exposed ...

Sex Delta by Cell Type. In men with Alzheimer’s (top left), B cells (red boxes) were fewer (blue), while NK cells (blue boxes ...

High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs) exposed to clinically relevant promoter molecules of inflammation. Revelation ...